Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

Inclusion Criteria: 1. Histologically confirmed unresectable advanced or metastatic non-small cell lung cancer (NSCLC) (stage IIIB or IV) 2. Chemotherapy naïve patient (Previous adjuvant or neoadjuvant chemotherapy allowed if the last dose was administered equal to or greater than 6 months ago.) 3. Age \> 18 4. Performance status 0 to 2 by Eastern Cooperative Oncology Group (ECOG) criteria 5. At least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 6. Adequate organ functions (assessed within 14 days of starting treatment) 1) Bone marrow: Absolute neutrophil count ≥ 1,500/mm³, Platelet count ≥ 100,000/mm³, Hemoglobin ≥ 9.0 mg/dL 2) Liver: Total bilirubin ≤ 1.5 x ULN; aspartic transaminase (AST) and alanine transaminase (ALT), alkaline phosphatase(ALP) ≤ 2.5 x ULN 3) Kidney: Serum creatinine ≤ 1.5 x ULN 7. Signed informed consent document Exclusion Criteria: 1. Clinically significant serious illness or medical condition (infection) 2. Prior systemic chemotherapy or immunotherapy for advanced NSCLC. 3. Presence of uncontrolled brain or leptomeningeal metastases 4. Prior radiotherapy within 3 weeks of starting treatment 5. Peripheral neuropathy equal to or greater than grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 6. Pregnant or lactating 7. Absolute contraindication of corticosteroid use 8. Patients with a history of severe hypersensitivity reaction to docetaxel, carboplatin, vinorelbine or gemcitabine